Compare State Street SPDR S&P Biotech ETF (XBI) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR S&P Biotech ETF vs Xcel Energy Inc — how do they compare? State Street SPDR S&P Biotech ETF trades at $159.35, while Xcel Energy Inc trades at $77.47 (market cap $48.51B). The key difference: Xcel Energy Inc pays a 3.05% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Xcel Energy Inc nearer its low. Which is the better fit depends on your goals.
| XBI | XEL | |
|---|---|---|
Sector | Broad Market / Factor | Utilities |
52-Week High | $164.28 | $83.91 |
52-Week Low | $86.92 | $71.75 |
Market Cap | — | $48.51B |
Enterprise Value | — | $86.82B |
Dividend Yield | — | 3.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Xcel Energy (XEL) trades at $78.33, up 1.9% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings of $0.93 per share, beating estimates, driven by infrastructure investment recovery. Revenue for 2025 was $14.67 billion with a net income margin of 15.28%. Analysts maintain a consensus buy rating with a $93.80 price target, highlighting growth from a $60 billion capital plan through 2030.
The outlook for XEL is positive due to projected EPS growth and rising electricity demand, but risks include regulatory pushback on rate increases and high capital expenditure. The stock offers stability with a dividend yield, yet valuation remains near historical highs, requiring careful monitoring of execution against its expansive investment strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
